Atom Therapeutics Joins Gout Education Society on Gout Awareness Day, May 22, to Help Educate the Public on Risk Factors and Treatment Options for This Growing Disease
ZHEJIANG, China, May 22, 2025--(BUSINESS WIRE)--Gout is the most common form of inflammatory arthritis: More than 12 million Americans suffer from the disease, and this number continues to rise. But in addition to being prevalent, serious and extremely painful, gout is also widely misunderstood by the public.
May 22 marks Gout Awareness Day—a day set aside each year since 2006 to educate on the severity of gout and encourage proper diagnosis and treatment. The need to keep this disease top-of-mind remains strong, notes N. Lawrence Edwards, MD, MACP, MACR, chairman of the non-profit Gout Education Society, which founded Gout Awareness Day 19 years ago.
"Gout is a serious condition that can lead to permanent joint damage if left untreated. By raising awareness, we hope to encourage individuals to seek proper treatment and manage their condition effectively," he explained. "While this is a priority for the Gout Education Society each and every day, Gout Awareness Day enables us to join with like-minded individuals and organizations to advocate for better quality of life for patients and their families through education and awareness."
Dr. William Shi, Founder, CEO and Chairman of Atom Therapeutics, which is developing new therapies to address gout, echoed Dr. Edwards' comments: "Over the last 30 years, the percentage of people developing gout has been steadily rising, yet many don't understand their disease. Furthermore, only one in three report taking their daily medications as prescribed to lower uric acid levels. We support the Gout Education Society's efforts to improve the quality of care and minimize the burden of gout."
Gout is caused by elevated uric acid levels. Over time, uric acid can accumulate and form crystals in the joints and other tissues—leading to painful flares. Untreated, gout can lead to permanent bone, joint and tissue damage, and other serious health issues, including kidney disease, heart disease and diabetes.
In conjunction with Gout Awareness Day, the Gout Education Society and Atom Therapeutics urge gout sufferers to learn more about the disease, seek immediate treatment and take ongoing steps to manage gout—with the most important step being to check uric acid levels every six months and aim for a healthy target of 6.0 mg/dL or below. While uric acid-lowering medications are typically needed to control gout and reduce future risks, those with gout should also make lifestyle changes—which includes following a healthy and balanced diet.
About Atom Therapeutics
Atom Therapeutics Ltd. is a fast-growing innovative drug company focused on the development of best in class small molecule therapeutics for treatment of inflammatory and metabolic diseases. The company's lead product, lingdolinurad (ABP-671), is in late-stage clinical development for treatment of chronic gout. Another small molecule ABP-745, for anti-inflammatory and autoimmune conditions, has completed Phase 1 clinical trials in the US and demonstrated good pharmacokinetics and safety, and has initiated Phase 2 clinical trial. For more information please visit: https://atomthera.us/
View source version on businesswire.com: https://www.businesswire.com/news/home/20250522595360/en/
Contacts
Media contactDaniel EramianOpus Biotech Communications425-306-8716
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
21 minutes ago
- Yahoo
Trividia Health introduces 5-Bevel Pen Needles in UK
Trividia Health UK has launched the TRUEplus 5-Bevel Pen Needles in the country, marking the product's first entry outside the US. The new line of insulin pen needles is said to provide healthcare professionals with a range of needle gauges and sizes to offer their diabetic patients, emphasising cost-effectiveness. The needles are engineered for enhanced comfort and are available in sizes, including 31 Gauge 5mm; 6mm; and 8mm, as well as 32 Gauge 4mm. Their design aims to enhance the injection experience and encourage individual compliance. Trividia's TRUEplus 5-bevel pen needles are said to offer an enhanced alternative to the older 3-bevel needle designs, which the company reports are less comfortable and may be expensive for patients. The TRUEplus brand, along with other retail pharmacy brand names, has distributed the 5-bevel pen needles across the US. Trividia Health CEO and president Jonathan Chapman said: 'Providing accessibility to a range of products for patients to confidently manage their diabetes is a priority for us at Trividia Health. 'Having the TRUEplus 5-Bevel Pen Needles as registered products in the UK allows healthcare providers the option to provide patients with high-quality, low-cost pen needles to manage their diabetes.' The company has expanded its diabetes care portfolio with the TRUENESS blood glucose monitoring system, launched in September 2024. TRUENESS offers cost-effective blood glucose management with options such as the TRUENESS AIR meter, which connects to the TRUE MANAGER AIR APP via Bluetooth, helping users link their daily activities with blood glucose levels. US-based consumer health and wellness organisation Trividia Health is the parent company of Trividia Health UK. "Trividia Health introduces 5-Bevel Pen Needles in UK" was originally created and published by Medical Device Network, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Medscape
22 minutes ago
- Medscape
Lp(a): Aiming at a Moving Target, Waiting for Ammunition
The evidence implicating high levels of lipoprotein(a), or Lp(a), as a risk predictor for heart attack, stroke, and other cardiovascular conditions has outpaced the science of what to do about the marker. But recent studies may be challenging the prevailing thinking about Lp(a) by showing it may also be predictive of atherosclerotic cardiovascular disease (ASCVD) away from the heart, such as carotid artery stenosis and peripheral artery disease, and that follow-up testing may benefit people with borderline levels of the blood fat. Before clinicians do anything about elevated Lp(a), however, they must first test for it. And experts in interventional cardiology have acknowledged that testing for Lp(a) as part of the cardiometabolic lipid panel lags far behind where it should be. Nishant P. Shah, MD, a specialist in cardiometabolic intervention at Duke University in Durham, North Carolina, led a retrospective study last year of five large US health systems. He and his colleagues found that only 0.4% of patients with ASCVD had been tested for Lp(a). Nishant P. Shah, MD 'Lp(a) testing is extremely low across the country, even in patients who have had established cardiovascular disease or established cardiovascular events,' Shah told Medscape Medical News .'There are disparities in who is getting tested for Lp(a). Our study showed that patients of the Black race, older patients, those with high BMIs, and women are less likely to be tested than others.' In other words, testing lags even further behind in at-risk groups. The lack of testing Shah's group reported among people with ASCVD has been confirmed by other studies. A 2023 study from Germany found similarly low rates, and a US database study the same year reported rates of 0.7% in patients on lipid-lowering therapies for secondary prevention of ASCVD. As a result, the American Heart Association launched a nationwide program, called the Community Health Centers Discovery Project, to bring Lp(a) testing to 20 community health centers across the country. Kaavya Paruchuri, MD 'Research shows that individuals from racially and ethnically diverse backgrounds are both more likely to have elevated Lp(a) levels and to experience disproportionate rates of heart disease,' said Kaavya Paruchuri, MD, a preventive cardiologist at Massachusetts General Hospital in Boston and an American Heart Association volunteer. 'By expanding access to Lp(a) testing in these settings, we can help identify patients at increased risk and support more informed conversations about prevention and risk-reduction strategies.' Barriers to Testing The barriers to more widespread testing are 'multifactorial,' Shah said. The relevance of Lp(a) has only emerged in the past decade or so, leaving generations of cardiologists and primary care providers lacking education about the marker. No Lp(a)-lowering drug has been approved, and while no fewer than six investigational agents are in clinical trials, none is on the brink of approval. The 2018 clinical guidelines from the American Heart Association/American College of Cardiology recommended selective screening; that is, people who have severe high cholesterol, ASCVD, or a family member who's had early ASCVD. In Europe, clinical guidelines recommend Lp(a) screening for all adults to identify those with high levels of the substance. 'Unfortunately, awareness of Lp(a) as a cardiovascular risk factor remains low amongst both patients and clinicians,' Paruchuri said. 'Furthermore, clinicians may be hesitant to order Lp(a) as there is no clearly defined treatment available to lower Lp(a), and they are unsure how to optimally handle abnormally elevated Lp(a) results.' Shah also noted that some health insurance plans do not cover the test. 'Providers may not know if the test is covered by insurance or not,' he said. The 2018 US guidelines noted that Lp(a) is a modified form of low-density lipoprotein (LDL) that appears to possess atherogenic potential. The consensus among researchers who have investigated Lp(a) is that it is a genetic biomarker. As such, levels may not vary from one test to the next unless Lp(a) is targeted with a drug. Lp(a) levels ≥ 50 mg/dL are considered to be elevated. Despite the lack of a treatment, experts said one case for the cost-effectiveness of Lp(a) testing is that it would be a once-and-done assay in most patients with risk factors for ASCVD. Emerging Revelations About Lp(a) 'I don't have the Lp(a) test repeated for patients, as I have not seen any strong evidence supporting that it being reduced or increased changes cardiovascular disease or other health issues,' Robert C. Block, MD, MPH, preventive cardiologist at the University of Rochester Medical Center, in Rochester, New York, told Medscape Medical News . 'Not repeating it also is more cost-effective. My point when seeing patients is that this makes sense until we have clinical trial data supporting that lowering it via an agent changes risk.' Robert C. Block, MD, MPH But a just-published study of almost 12,000 adult patients at three Mayo Clinic locations may upend that thinking. The Mayo researchers said that after one Lp(a) test, normal or high levels typically do not change: 96.4% of people with normal Lp(a) and 89.9% with high levels in the study had the same levels of the molecule when they were retested. However, the study did find that almost half of the people with borderline Lp(a) — a range of 30 to 50 mg/dL — changed their category (normal, borderline, or high) after retesting, and a quarter of them had a change greater than 10 mg/dL. Women, patients who had ASCVD, those with LDL cholesterol (LDL-C) levels of ≥ 100 mg/dL, or those on statin therapy had higher odds of a change in Lp(a) of > 10 mg/dL. 'These findings highlight that patients with borderline Lp(a) levels may require more than one Lp(a) measurement for a comprehensive ASCVD risk assessment,' the authors of the study wrote. Also adding a dimension to the understanding of Lp(a) is a large database analysis in the UK that has linked high Lp(a) to peripheral artery disease and carotid artery stenosis, among other extracoronary ASCVDs. Patients in the study — which used > 70 mg/dL (or 150 nmol/L) as a threshold for predicting ASCVD complications — with peripheral artery disease and elevated Lp(a) were at 57% greater risk for having a major adverse limb event than patients with normal concentrations of the molecule. Those with carotid stenosis and high Lp(a) had a 40% greater risk for stroke than patients with normal levels. According to the researchers, lowering Lp(a) concentrations by 35 mg/dL (75 nmol/L) would reduce the risk for incident peripheral artery disease by 18% and for incident carotid stenosis by 17%. 'Participants with established extracoronary atherosclerotic vascular disease and elevated Lp(a) concentrations are at high risk for progression to major atherosclerotic complications,' they reported. Again, however, how to reduce Lp(a) is unclear. Consistent intake of niacin is one strategy for reducing Lp(a), the UK researchers stated, but only 77 (0.02%) of the 460,544 participants in the analysis were taking the nutrient. Niacin has had its own star-crossed history as a risk-reduction strategy in ASCVD. Both the 2011 AIM-HIGH trial and the 2014 HPS2-THRIVE study found that people who took niacin supplements did not reduce their risk for ASCVD, although participants in AIM-HIGH on niacin had a 25% reduction in Lp(a) levels. These studies moved the consensus away from niacin therapy. Another recent revelation about Lp(a) is its apparent independence from LDL-C. Lowering LDL-C with statins does not affect cardiac risks associated with elevated Lp(a), said Sotirios Tsimikas, MD, who was the corresponding author for a 2024 meta-analysis on the question. Sotirios Tsimikas, MD 'Lp(a) is an independent risk factor at all levels of achieved LDL when you treat somebody with an LDL-lowering agent,' said Tsimikas, a cardiologist at the Sulpizio Cardiovascular Center and director of vascular medicine at the University of California San Diego (UCSD) Health. 'The implication is you have to treat it as your own independent risk factor and not assume that when you treat the LDL-C, even at very low levels, that you reduce Lp(a)-mediated risk.' In a study, patients with Lp(a) > 50 mg/dL but in the lowest quartile of LDL-C after treatment — in the 3.1-77 mg/dL range — had a 38% greater ASCVD risk than those with Lp(a) levels below the 50 mg/dL threshold. Tsimikas said this study built on research his group published in 2018. 'What this paper showed with more granularity was that the LDL level that was achieved in the statin trials did not reduce the Lp(a) risk,' he said. The State of Clinical Trials Block and his group have reported on clinical trials of six investigative therapies targeting Lp(a). Three subcutaneous therapies are in phase 3 trials: Pelacarsen, an antisense oligonucleotide that has demonstrated an 80% reduction in Lp(a); and two small interfering RNAs (siRNAs), olpasiran and lepodisiran, both of which have demonstrated up to a 98% reduction in Lp(a). Likewise, three agents are in phase 2 trials: Zeriasiran, a subcutaneous siRNA agent that has shown up to a 98% reduction in Lp(a); and two oral agents, muvalaplin, an Lp(a) inhibitor that has demonstrated up to an 85% reduction in levels of the molecule, and obicetrapib, a cholesterol ester transport protein inhibitor that has shown up to a 57% reduction in the substance and is used in conjunction with evolocumab. Deeper in the pipeline is at least one potential one-time gene therapy, CTX320, which is in preclinical stages. The pelacarsen trial is scheduled for completion early next year. The olpasiran trial is scheduled for completion at the end of 2026. 'We're right on the cusp of knowing if we lower Lp(a), do we get a benefit that's clinically meaningful?' Tsimikas said. Modify What You Can — Wait for the Calvary Despite the lack of commercially available therapies, providers can employ several interventions to manage ASCVD risks in patients with elevated levels of Lp(a). 'The theme here is to modify what you can modify until we have more directed therapy with good clinical trial outcomes,' Shah said. 'Drop LDL as low as you can. Consider starting aspirin therapy, especially if patients have multiple risk factors — and absolutely they should be on aspirin therapy if they've had a prior cardiovascular event. Then I look to modify other things. Are they hypertensive? Can I get them better? Are they obese? Can I reduce their weight? Do they have diabetes? What can we do to control this more?' First-degree relatives of people with high Lp(a) levels should get their Lp(a) levels tested, he added. Motivated patients could be encouraged to enroll in a clinical trial. 'As more people understand that there are changes you can make today, they may be more likely to test for Lp(a),' Shah said. Until clinical trial results are reported, clinicians are in a 'gray zone,' Tsimikas said. To get through that 'gray zone,' more education of providers and patients is needed, healthcare systems need to support more widespread Lp(a) testing, and insurance companies need to cover testing, he said. 'What I'm seeing is that a lot of physicians have become aware of Lp(a), and I'm seeing a lot of testing that normally I wouldn't,' Tsimikas said. 'I think the tide is already turning on this.' Block has no relevant relationships to disclose. Paruchuri reported having financial relationships with Allelica, Amgen, Apple, AstraZeneca, Boston Scientific, Genentech/Roche, Ionis, Novartis, and NewAmsterdam Pharma. Shah reported having received research grants from Amgen and Janssen and is a consultant/advisor for Esperion, Amgen, and Novartis. Tsimikas is a co-inventor and receives royalties from patents owned by UCSD. He is also a cofounder and holds equity in Oxitope and Kleanthi Diagnostics and has a dual appointment at UCSD and Ionis Pharmaceuticals.
CNN
22 minutes ago
- CNN
‘It's just PR': Skittles, Hershey and Nestle are removing artificial colors
The Trump administration declared victory after Kraft Heinz, Skittles and General Mills made splashy announcements to remove artificial colors — even taking credit for Coca-Cola's plan to replace high-fructose corn syrup with US cane sugar in a new version this fall. 'President Trump delivers on MAHA (Make America Healthy Again) push,' the White House said last month, touting the companies' changes to 'confront the chronic health crisis plaguing Americans.' But nutritionists and public health researchers don't buy the hype. So far, companies have only made performative changes, they say, many of which were long in the works due to consumer demand for natural ingredients. Meanwhile, the administration's funding cuts for health care, food stamps, research and public health programs run contrary to its goal of making Americans healthier. 'These are cosmetic changes with no health impact. They just allow the MAHA people to say they had a victory,' said Dr. Barry Popkin, a professor of nutrition at the University of North Carolina. 'It's just PR.' Health advocates do credit Robert F. Kennedy Jr., the Health and Human Services Department secretary, and his MAHA movement for bringing attention to unhealthy foods, chronic disease and major companies' influence on the food system in America. But researchers say Kennedy's focus on synthetic dyes misses the larger problem of the prevalence of cheap, convenient foods loaded with salt, sugar and fat. Ice cream is still ice cream and soda is still soda, even without artificial flavors, Popkin said. A spokesperson for the HHS said Kennedy is 'dismantling the status quo that fueled a nationwide chronic disease epidemic' and 'eliminating bureaucracy and restoring integrity to federal health programs.' 'HHS is confronting the root causes of chronic illness that previous administrations were too timid to address,' the spokesperson added. But for Kennedy and the administration to make a substantive impact on Americans' diets, researchers say they will have to implement policies that tightly regulate ultraprocessed foods. Ultraprocessed foods account for up to 70% of the US food supply, and include many popular brands of chips, cookies, candy, ice cream and pre-made meals. Studies have frequently linked them to obesity, cancer, diabetes, heart disease and other health disorders. Kennedy has called the easy availability of these foods a 'crisis,' and oversaw the White House's Make America Healthy Again Commission report released in May that identifies ultraprocessed foods as a key contributor to a national rise in chronic illnesses — particularly among children. The agency has yet to enact any significant measures to cut down on ultraprocessed foods. 'Right now, they're not going after the real food culprit,' Popkin said. 'If Kennedy does anything significant on ultraprocessed foods, it will be hugely important for health.' Synthetic dyes, made from petroleum, are often used to make food and beverages brightly colored and appealing to customers, especially children. But they have potential negative effects on animal and human health, including possible increased risk of cancer and neurobehavioral issues in some children. In January, the US Food and Drug Administration banned red dye No. 3 in food, beverages and ingested drugs. Kennedy has been pressuring food companies to voluntarily remove all food dyes from their products. But many have been moving away from synthetic dyes for years due to pressure from consumers, health advocates and bans or restrictions in states like California, Virginia and West Virginia. For example, both Kraft Heinz and General Mills — which the administration recently celebrated for pledging to remove synthetic colors — have already removed the additives from most of their products. '(As) much as I love the idea of getting rid of artificial colors, doing so is a nutritionally meaningless way of giving compliant junk foods the aura of health foods,' said Dr. Marion Nestle, an emeritus professor of nutrition and food studies at New York University. Roughly 64% of consumers now actively look for snacks perceived as 'good for them,' a figure that has increased sharply in recent years, according to market research firm Circana. Yogurt, cheeses and foods and drinks with protein have proliferated due to their nutritional appeal. This is also not the first time companies have made voluntary pledges to remove artificial dyes from their products. But many have backtracked on their commitments. 'We hope industry will voluntarily improve the food supply this time around,' said Aviva Musicus, the science director at the Center for Science in the Public Interest, a nonprofit consumer advocacy group. 'There has to be a plan to hold industry accountable for when they inevitably don't cooperate. I haven't seen that for this administration.' The Consumer Brands Association, a trade group representing major food, beverage and household product companies, did not respond directly to this criticism. But the group pointed to an April statement that said the industry has 'always prioritized transparency and it will continue to lead the way to ensure consumers have the information they want and need to make informed purchasing decisions.' And slapping foods with a broad definition of ultraprocessed may result in 'demonizing safe, shelf-ready foods' that will limit consumers' access to nutritious foods, the group said. While HHS focuses on food additives, many of the Trump administration's other policies weaken government efforts to improve the food supply and Americans' health, critics say. Trump's sweeping tax and spending cuts package is expected to leave 10 million more people without health insurance in 2034, according to a Congressional Budget Office estimate. More than 22 million families will lose some or all of their Supplemental Nutrition Assistance Program (SNAP) benefits, according to the Urban Institute. The law eliminated funding for programs that offer cooking classes and nutrition education for SNAP recipients, and the Agriculture Department cut two pandemic-era programs that help schools and food banks buy from local farmers. 'While MAHA leadership celebrates hollow wins, we've seen the federal government cut SNAP benefits for millions of Americans, rip millions from their health insurance coverage (and) slash programs to help farmers bring local foods into schools,' Musicus said. The administration is not just cutting health care and food benefits — it also slashed billions in research funding and fired thousands of employees at the National Institutes of Health, Centers for Disease Control and other agencies. The top nutrition researcher at NIH, who focused on studying ultraprocessed foods, left the agency, citing censorship under Kennedy. (HHS previously denied the claims.) These research cuts and layoffs may make it impossible to enact stricter rules or investigate the food industry, said Dr. Jerold Mande, an adjunct professor at the Harvard School of Public Health and a senior policy official in the Obama and Clinton administrations. 'They've also lost tens of thousands of people across government to do these investigations,' he said. At the same time, some health experts are hopeful Kennedy will seize on political momentum to make major policy changes to improve Americans' diets. 'I do give RFK Jr. a lot of credit for making chronic disease caused by our food, principally obesity, a political priority,' Mande said. 'I give them an incomplete in terms of what they're going to do about it.' In August, the MAHA Commission will release the second report on its strategy for improving childhood chronic obesity. Advocates will be looking to see if the report signals the administration may try to mandate front-of-package warning labels or crack down on marketing junk food to children. The report may also provide clues to whether the administration will create dietary guidelines with recommendations for limits to ultraprocessed foods. These would be major moves, but they may clash with the administration's deregulatory agenda. 'People are right to question what the lasting policy change is going to be,' Mande said, noting that removing artificial colors matters only if Kennedy is 'laying the groundwork to take on ultraprocessed food broadly.' CNN's Kristen Rogers contributed to this article.
